Navigation Links
Moffitt researchers develop new way to combat drug resistance for melanoma patients
Date:6/30/2014

TAMPA, Fla. (June 30, 2014) Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

Scientists have made significant strides identifying important molecules that contribute to melanoma growth and metastases, such as the proteins BRAF and MEK. Therapeutic agents that target these molecules have shown promise in the clinic, and many patients have significant reductions in tumor growth and tumor burden.

"While targeted therapy drugs, such as BRAF and MEK inhibitors, have been associated with impressive responses in melanoma patients, most patients will eventually fail therapy," said Keiran Smalley, Ph.D., associate member of the Cancer Biology and Evolution Program at Moffitt.

Tumors can develop different resistance mechanisms and adapt to targeted agents in order to survive and continue to grow. "It is likely that long-term management of melanoma patients will require combinations of drugs," said Smalley.

The molecular changes that lead to drug resistance vary between patients and each tumor. Identifying these molecular alterations with current scientific approaches is difficult, costly and time-consuming.

Smalley's team, in conjunction with the lab of John Koomen, Ph.D. of Moffitt's Chemical Biology and Molecular Medicine Program, developed a liquid chromatography-multiple reaction monitoring mass spectrometry assay to analyze more than 80 proteins known to be important in melanoma progression and resistance to targeted therapies. They showed that melanoma cells that are resistant to drugs that target MEK have alterations in a number of different cell signaling pathways. Results like this will allow for the development of new treatment strategies.

The researchers plan to expedite the identification of proteins involved in melanoma drug resistance through the use of liquid chromatography-multiple reaction monitoring mass spectrometry. The platform allows the simultaneous detection of multiple proteins in small quantities of tissue samples. It also results in highly reproducible data that can be easily validated among different laboratories.


'/>"/>

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt study shows utilizing genetic health care professional reduces unnecessary testing
2. Moffitt researchers develop process to help personalize treatment for lung cancer patients
3. Ohio State and Moffitt form worlds largest cancer research collaboration for big data
4. Moffitt Cancer Center instrumental in new clinical guidelines for cancer-related fatigue
5. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
6. Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
7. Moffitt instrumental in FDA approval of revolutionary 2-drug combo to treat advanced melanoma
8. Moffitt Cancer Center launches prostate cancer study focused on black men
9. Single injection may revolutionize melanoma treatment, Moffitt study shows
10. Moffitt researchers identify gene variations that may help predict cancer treatment response
11. Moffitt Cancer Center expert standardizing guidelines for penile cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... (PRWEB) , ... December 02, 2016 , ... ... will give patients better access to nutraceuticals and help doctors more efficiently manage ... patient portal and practice management software platform for Integrative and Functional Medicine. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-Aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold ... certified and experienced Indoor Air Quality Companies in VA, MD and DC, recently completed ... , The new mold law in the district of Columbia is a good ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... documentary on the perils of heroin that was watched live by 1 million ... Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite School ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... Taiwan , Dec. 5, 2016 ... non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... profile of ropeginterferon alfa-2b versus HU AOP ... follow-up trial CONTINUATION-PV to obtain European marketing authorization in the ... data to the FDA as it seeks approval for commercialization ...
(Date:12/4/2016)... --  Pairnomix, LLC, a genetic research company and member ... White House, today announced that findings from its first case ... therapies for a patient with epileptic encephalopathy caused by a ... the 70 th Annual Meeting of the American ... December 2-6, 2016.  Pairnomix, unique process involves creating ...
Breaking Medicine Technology: